Effects on the hemostatic system and liver function in relation to implanon® and norplant®: A prospective randomized clinical trial

Contraception

Volumn 58, Issue 2, 1998, Pages 93-98

  Egberg, Nils ^a   Van Beek, Agaath ^b   Gunnervik, Christina ^c   Hulkko, Seppo ^d   Hirvonen, Erkki ^e   Larsson Cohn, Ulf ^f   Bennink, Herjan Coelingh ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NV ORGANON   (Netherlands)

^c Kvinnokliniken ^*  (Sweden)

^d Lääkärikeskus Hemo Oy   (Finland)

^e Kalevankadun Laakariasema   (Finland)

^f LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Contraceptive implant; Etonogestrel 3 ketodesogestrel; Hemostatis; Implanon ; Levonorgestrel; Liver function; Norplant

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BLOOD CLOTTING FACTOR 7; ETONOGESTREL; GAMMA GLUTAMYLTRANSFERASE; LEVONORGESTREL; SILICONE;

ARTICLE; BODY MASS; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED STUDY; FEMALE; HEMOSTASIS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; LIVER FUNCTION TEST; NORMAL HUMAN; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL; THROMBOGENESIS; THROMBOSIS;

ADULT; CONTRACEPTIVE AGENTS, FEMALE; DESOGESTREL; FEMALE; HEMOSTASIS; HUMANS; LEVONORGESTREL; LIVER; LIVER FUNCTION TESTS; PROGESTERONE CONGENERS; PROSPECTIVE STUDIES; VINYL COMPOUNDS;

EID: 0032144827     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(98)00070-5     Document Type: Article

References (26)

1. Vessey M., Mant D., Smith A., Yeates D. Oral contraceptives and venous thromboembolism findings in a large prospective study . Br Med J. 292:1986;526.
2. Böttiger L.E., Boman G., Eklund G., Westerholm B. Oral contraceptives and thromboembolic disease effects of lowering oestrogen content . Lancet. i:1980;1097-1101.
3. Gerstman B.B., Piper J.M., Tomita D.K., Ferguson W.J., Stadel B.V., Lundin F.E. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol. 133:1991;32-37.
4. Venous thromboembolic disease and combined oral contraceptives results of international multicentre case-control study . Lancet. 346:1995;1575-1582.
5. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet. 346:1995;1582-1588.
6. Jick H.H., Jick S.S., Gurewich V., Wald Myers M., Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 346:1995;1589-1593.
7. Spitzer W.O., Lewis M.A., Heinemann L.A.J., Thorogood M., MacRae K.D. Third generation oral contraceptives and risk of venous thromboembolic disorders an international case-control study . Br Med J. 312:1996;83-88.
8. Mäkäräinen L., van Beek A., Tuomivoara L., Asplund B., Coelingh Bennink H. Ovarian function during the use of a single contraceptive implant Implanon compared with Norplant . Fertil Steril. 69:1998;714-721.
9. ® subdermal contraceptive implant system. IPPF Med Bull. 29:1995;1-4.
10. ® implants on haemostatic function. Contraception. 45:1992;203-219.
11. ®-2 rods on haemostatic function. Contraception. 46:1992;71-81.
12. Singh K., Viegas O.A.C., Loke D.F.M., Ratnam S.S. Effect of Norplant implants on liver, lipid and carbohydrate metabolism. Contraception. 45:1992;141-153.
13. Singh K., Viegas O.A.C., Loke D.F.M., Ratnam S.S. Effect of Norplant-2 rods on liver, lipid and carbohydrate metabolism. Contraception. 45:1992;463-472.
14. Guidelines for the Toxicological and Clinical Assessment and Post-Registration Surveillance of Steroidal Contraceptive Drugs. Geneva: WHO Special Programme of Research, Development and Research Training in Human Reproduction, 1987.
15. Vermylen C., de Vreker R.A., Verstraete M. A rapid enzymatic method for assay of fibrinogen; fibrin polymerization time (FPT test). Clin Chim Acta. 8:1963;418-424.
16. Aurell L., Friberger P., Karlsson B., Claeson G.A. New sensitive and highly specific chromogenic peptide substrate for factor Xa. Thromb Res. 11:1977;595-609.
17. Bergström K., Egberg N. Determination of vitamin K-sensitive coagulation factors in plasma. Studies on three methods using synthetic chromogenic substrates. Thromb Res. 12:1978;531-547.
18. Matthews J.N.S., Altman D.G., Campbell M.J., Royston P. Analysis of serial measurements in medical research. Br Med J. 300:1990;230-235.
19. Tietz N.W. Clinical Guide to Laboratory Tests. 2nd ed. 1990;605 WB Saunders, Philadelphia.
20. Dahlbäck B., Carlsson M., Svensson P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C prediction of a cofactor to activated protein C . Proc Natl Acad Sci USA. 90:1993;1004-1008.
21. Bertina R.M., Koeleman B.P.C., Koster T., et al. Mutation in blood coagulation factor V associated with resistance of activated protein C. Nature. 369:1994;64-67.
22. Winkler U.H., Oberhoff C., Bier U., Schindler A.E., Gillain D. Haemostatic effects of two oral contraceptives containing low doses of ethinyl estradiol and either gestodene or norgestimate an open, randomized, parallel-group study . Int J Fertil. 40:1995;260-268.
23. Pabinger I., Schneider B. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. Thromb Haemost. 71:1994;548-552.
24. Jespersen J. Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients. Dan Med Bull. 35:1988;1-33.
25. Fruzzetti F., Ricci C., Fioretti P. Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives. Contraception. 49:1994;579-592.
26. McCann M.F., Potter L.S. Progestin-only oral contraception a comprehensive review . Contraception. 50:(suppl 1):1994;S61-S62.